UNITED THERAPEUTICS Corp (UTHR)
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Address
1000 SPRING ST
SILVER SPRING, MD 20910
Founded
1996
Number of Employees
1,168
Website
http://www.unither.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
$403,167 | $394,487 | $499,998 | $253,705 | - | - | - | - | - | - | - | $387,839 |
| Average Price | $96.55 | $166.55 | $119.48 | $128.34 | - | - | - | - | - | - | - | $122.10 |
| # Shares Purchased | 4,175,579 | 2,368,645 | 4,184,911 | 1,976,788 | - | - | - | - | - | - | - | 3,176,481 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | 251.1% | 103.5% | 183.7% | 164.1% | - | - | - | - | - | - | - | 177.6% |
| S&P 500 Return to Date | 181.9% | 173.0% | 168.6% | 129.7% | - | - | - | - | - | - | - | 163.3% |
| Excess Total Return | 69.2% | -69.4% | 15.1% | 34.4% | - | - | - | - | - | - | - | 14.4% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | 81% | 59% | 75% | 80% | - | - | - | - | - | - | - | 92% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at UTHR make a trade.
Creating a free account takes less than one minute